Estimating quality-adjusted time without symptoms or toxicity using a multivariate failure time regression model

被引：0
|
作者：
Wang, J [1 ]
Sherrill, B [1 ]
Irish, WD [1 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67166-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A8 / A9
页数：2
相关论文
共 50 条
  • [1] ESTIMATING QUALITY-ADJUSTED LIFE YEARS (QALYS) THROUGH QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY (QTWIST) IN RCTS: AN ALTERNATIVE TO ECONOMIC MODELLING
    Briggs, A.
    Marian, M.
    Ohsfeldt, R. L.
    Dick, K.
    [J]. VALUE IN HEALTH, 2019, 22 : S104 - S104
  • [2] Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma
    Zee, B
    Cole, B
    Li, T
    Browman, G
    James, K
    Johnston, D
    Sugano, D
    Pater, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2834 - 2839
  • [3] Systematic review and benchmarking of Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) in oncology
    Solem, Caitlyn T.
    Kwon, Youngmin
    Shah, Ruchit M.
    Aly, Abdalla
    Botteman, Marc F.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (03) : 245 - 253
  • [4] Quality-adjusted time without symptoms or toxicity (Q-TWiST) in oncology studies: is there a standard approach?
    Simpson, Sarah
    Brohan, Elaine
    Cocks, Kim
    [J]. QUALITY OF LIFE RESEARCH, 2016, 25 : 122 - 123
  • [5] Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma
    Beaumont, Jennifer L.
    Salsman, John M.
    Diaz, Jose
    Deen, Keith C.
    McCann, Lauren
    Powles, Thomas
    Hackshaw, Michelle D.
    Motzer, Robert J.
    Cella, David
    [J]. CANCER, 2016, 122 (07) : 1108 - 1115
  • [6] THE QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS AND TOXICITY (Q-TWIST) IN (IMMUNO)-ONCOLOGY: A SYSTEMATIC REVIEW OF THE LITERATURE
    Wan, Y.
    Tai, M.
    Botteman, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A385 - A385
  • [7] Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
    Barretina-Ginesta, Maria-Pilar
    Monk, Bradley J.
    Han, Sileny
    Pothuri, Bhavana
    Auranen, Annika
    Chase, Dana M.
    Lorusso, Domenica
    Anderson, Charles
    Abadie-Lacourtoisie, Sophie
    Cloven, Noelle
    Braicu, Elena, I
    Amit, Amnon
    Redondo, Andres
    Shah, Ruchit
    Kebede, Nehemiah
    Hawkes, Carol
    Gupta, Divya
    Woodward, Tatia
    O'Malley, David M.
    Gonzalez-Martin, Antonio
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [8] Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia
    Sharman, Jeff P.
    Miranda, Paulo
    Roos, Jack
    Emeribe, Ugochinyere
    Cai, Ling
    Liljas, Bengt
    Gaitonde, Priyanka
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 (07) : 1243 - 1252
  • [9] Quality-adjusted time without symptoms or toxicity (Q-TWiST): patient-reported outcome or mathematical model? A systematic review in cancer
    Tate, Wendy R.
    Skrepnek, Grant H.
    [J]. PSYCHO-ONCOLOGY, 2015, 24 (03) : 253 - 261
  • [10] Quality-adjusted time without symptoms and toxicity (Q-twist) of fotemustine compared with dacarbazine in patients with disseminated malignant melanoma
    Simons, W. R.
    Aamdal, S.
    Hauschild, A.
    Mohr, P.
    Grob, J. J.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A322 - A322
12345